- Home
- KYTX
as 07-26-2024 4:00pm EST
Stocks
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
| Founded: | 2018 | Country: | Canada |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 431.6M | IPO Year: | 2024 |
| Target Price: | $29.00 | AVG Volume (30 days): | 577.2K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.75 - $30.60 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 33.33% |
Stock Insider Trading Activity of KYVERNA THERAPEUTICS INC (KYTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | KYTX | 10% Owner | Feb 12 '24 | Buy | $22.00 | 450,000 | $9,900,000.00 | 3,163,868 | SEC Form 4 |
| Vida Ventures, LLC | KYTX | 10% Owner | Feb 12 '24 | Buy | $22.00 | 252,553 | $5,556,166.00 | 252,553 | SEC Form 4 |
| Vida Ventures, LLC | KYTX | 10% Owner | Feb 12 '24 | Buy | $22.00 | 583 | $12,826.00 | 583 | SEC Form 4 |
| Northpond Ventures III GP, LLC | KYTX | Feb 12 '24 | Buy | $22.00 | 450,000 | $9,900,000.00 | 450,000 | SEC Form 4 | |
| GILEAD SCIENCES, INC. | KYTX | 10% Owner | Feb 12 '24 | Buy | $22.00 | 910,000 | $20,020,000.00 | 4,126,119 | SEC Form 4 |
Latest KYVERNA THERAPEUTICS INC News
KYTX Breaking Stock News: Dive into KYTX Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Pharmaceutical Technology
10 days ago
Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate
Zacks
10 days ago
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
MT Newswires
11 days ago
Kyverna Therapeutics Gets FDA RMAT Designation for Stiff-Person Syndrome Treatment; Shares Rise After Hours
PR Newswire
11 days ago
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
PR Newswire
a month ago
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
PR Newswire
a month ago
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
PR Newswire
2 months ago
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Compare KYTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYTX KYVERNA THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.